Detailed price information for Merck & Company (MRK-N) from The Globe and Mail including charting and trades.
Tipranks Press Release.
Erasca targets the KRAS inhibitor market with early cancer data, Fast Track status, and 2027 trials ahead. Click to read this latest analysis of ERAS stock.
Erasca is a funded RAS-oncology fast follower with ~$1B liquidity. Click for more on ERAS stock.
On August 24, Erasca (NASDAQ:ERAS) announced that the FDA had granted Fast Track Designation to ERAS-0015, its oral pan-RAS molecular glue, for patients with metastatic pancreatic adenocarcinoma. The designation gives Erasca more frequent contact with regulators and, if the drug keeps clearing bars, a shot at accelerated approval, priority review, and rolling review. For a […]
Detailed price information for Gsk Plc ADR (GSK-N) from The Globe and Mail including charting and trades.
Designation follows encouraging Phase 1 activity across multiple tumor types including 2L+ KRAS G12X pancreatic cancer Three potentially...
This is the newest page. Registered accounts read further back.